Ilmarinen Mutual Pension Insurance Co Has $26.05 Million Stake in Pfizer Inc. (NYSE:PFE)

Ilmarinen Mutual Pension Insurance Co raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 48.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 982,000 shares of the biopharmaceutical company's stock after purchasing an additional 322,000 shares during the quarter. Ilmarinen Mutual Pension Insurance Co's holdings in Pfizer were worth $26,052,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Norges Bank acquired a new stake in shares of Pfizer in the 4th quarter valued at $2,328,986,000. Charles Schwab Investment Management Inc. boosted its position in Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after buying an additional 25,315,159 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Pfizer during the fourth quarter worth about $274,694,000. Massachusetts Financial Services Co. MA increased its holdings in shares of Pfizer by 7.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after buying an additional 5,350,381 shares in the last quarter. Finally, Fisher Asset Management LLC raised its stake in shares of Pfizer by 79.5% in the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company's stock valued at $295,760,000 after acquiring an additional 4,938,209 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on PFE shares. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $31.07.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Trading Down 2.9 %

Shares of Pfizer stock traded down $0.64 during trading on Wednesday, hitting $21.20. 42,242,441 shares of the company were exchanged, compared to its average volume of 46,990,594. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $120.22 billion, a P/E ratio of 15.03, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The firm's fifty day moving average price is $25.59 and its 200 day moving average price is $26.58. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.10 earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.